

Encorafenib BEACON CRC

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Encorafenib BEACON CRC

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
 Therapeutic Indication: Treatment of patients with mCRC with a BRAF V600E mutation, who have received prior systemic therapy
 Experimental Arm: Encorafenib + Cetuximab
 Control Arm: Either irinotecan or FOLFIRI with cetuximab

